Chemoendocrine Treatment Is Standard in Hormone Receptor-Positive Patients

Publisher： Karger

E-ISSN： 1661-3805|3|4|229-230

ISSN： 1661-3791

Source： Breast Care, Vol.3, Iss.4, 2008-08, pp. : 229-230

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Extended Adjuvant Endocrine Therapy in Hormone Receptor-Positive Early Breast Cancer

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 138-144

Karger

Access to resources Recommend Favorite

Is Chemoendocrine Treatment without Alternative?

By  

Breast Care, Vol. 3, Iss. 4, 2008-08 ,pp. : 231-235

Karger

Access to resources Recommend Favorite

Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review

By  

Breast Care, Vol. 12, Iss. 3, 2017-06 ,pp. : 168-171

Karger

Access to resources Recommend Favorite

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients

By  

Breast Care, Vol. 11, Iss. 1, 2016-02 ,pp. : 8-12

Karger

Access to resources Recommend Favorite

Systemic Treatment in Premenopausal Patients with Breast Cancer

By  

Breast Care, Vol. 10, Iss. 5, 2015-0 ,pp. : 305-306

Karger

Access to resources Recommend Favorite